06, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial ...

Based on the one-year price targets offered by 7 analysts, the average target price for Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is $10.14, with a high estimate of $14 and a low estimate of $6.